Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2020

View Archived Issues

Celiac model captures gluten, genetics and gut reactions

Autophagy helps repair lung injury

Strengthening lysosomes could head Parkinson's off at the pass

Neuropore receives a grant to developTLR2 agonist for ALS

PYC receives NHMRC grant to identify new antisense drugs

Arcus initiates phase II study of zimberelimab monotherapy and with immunotherapies in NSCLC

ModraDoc006 shows promising efficacy and safety in phase I study in mCRPC

Pfizer presents first interim analysis data from TALAPRO-1 study of talazoparib

Phase I data for guadecitabine plus cisplatin in patients with platinum-refractory GCT

Roche, Genentech describe new MEKKK1 inhibitors

New tachykinin NK1 receptor antagonists identified at XW Laboratories

Inventiva discloses new PPAR agonists

Mutabilis patents bacterial beta-lactamase inhibitors

Preclinical data presented for SIG-007 in models of Fabry disease

PD-1/PD-L1 interaction inhibitors described by Shanghai Ennova Biopharmaceutical

Progranulin gene therapy has therapeutic effects in knockout model

KRT5 and KRT20 found to predict treatment response in patients with muscle-invasive bladder cancer

PSA declines seen with 225Ac-DOTA-J591 in mCRPC trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.